The traditional drug-centric trial model is failing. The next evolution is trials designed to validate the *decision-making process* itself, using platforms to assign the best therapy to heterogeneous patient groups, rather than testing one drug on a narrow population.

Unlike controlled clinical trial data, real-world evidence is derived from vast, messy, and incomplete data from daily healthcare. This variability is its strength, offering deeper insights into long-term outcomes, drug interactions, and diverse patient populations that clean trial data misses.

To make clinical trials more representative of real-world SCLC patients, who are often too sick to enroll, a pragmatic approach is emerging. Allowing one initial cycle of stabilizing chemotherapy before trial inclusion is a key strategy to broaden eligibility and gather more relevant data.

Acadia's R&D process starts by considering what will ultimately matter to patients, physicians, and payers. This "end in mind" approach ensures clinical trials are designed to demonstrate meaningful, commercially relevant benefits. It forces realism about a drug's potential impact early in development, avoiding wasted resources on therapies that won't be adopted.

To generate reliable findings from real-world data, researchers must avoid data dredging. The best practice is to simulate a 'target trial' by creating a formal protocol with pre-defined inclusion criteria and a statistical plan, mirroring the rigor of a prospective clinical trial. This approach is even guided by the FDA.

Registrational clinical trials for prostate cancer drugs enroll patients who are substantially younger (median age 67-69) and healthier than the typical real-world patient (median age 73-74). This gap means trial data on efficacy and safety doesn't perfectly apply to the majority of patients seen in clinic.

Industry leaders often believe their clinical trial designs are patient-centric, but direct experience in community clinics reveals the significant burden placed on patients and caregivers, such as 12-hour blood draw days. This exposure leads to more practical and humane trial designs that improve real-world data collection.

Dr. Richardson repeatedly emphasizes that modern clinical trial design must incorporate FDA guidance. Key elements now considered vital for approval include upfront dose optimization phases and deliberate inclusion of diverse populations, particularly African American patients, to ensure relevance and equity.

Rachel Glenister argues that the best Randomized Control Trials (RCTs) are not those that simply test if a specific program works, especially if it's logistically complex and unscalable. Instead, the most valuable RCTs test a more fundamental, generalizable theory about human behavior, yielding insights that can be applied across many contexts.